Eli Lilly Grants Access to Unapproved Obesity Drug for 79-Year-Old Patient

Eli Lilly provided a 79-year-old patient with access to a powerful, yet unapproved, obesity medication, marking a rare move in drug accessibility. This raises questions about regulatory oversight and personalized treatment strategies. Next, authorities may investigate the criteria and implications of such access, impacting future drug approval processes.